Moreland Mary K 4

What Happened

• Mary K. Moreland, Executive Vice President of Abbott Laboratories (ABT), was granted performance-based restricted stock awards on February 24, 2026. The filing shows two award entries: 13,951 shares granted at $0.00 and 57,512 shares reported as a derivative award at $0.00 (total 71,463 shares). These were awards/grants (transaction code A), not open-market purchases or sales, so no cash changed hands.

Key Details

• Transaction date: February 24, 2026; Form 4 filed February 26, 2026 (appears timely).
• Grant amounts: 13,951 shares (direct award) and 57,512 shares (derivative award) — total 71,463 shares; reported price $0.00.
• Vesting/conditions: Footnote F1 states these are performance-based restricted stock awards under Abbott’s 2017 Incentive Stock Program with a 3-year term and up to 1/3 vesting per year subject to achieving a minimum return on equity target. The award permits share withholding for taxes.
• Footnote F2 notes a balance in the Abbott Stock Retirement Trust as of Feb 24, 2026 (amount not specified in the filing).
• Footnote F3 describes a separate employee stock option schedule (exercisable in annual increments of 19,170 / 19,171 / 19,171 beginning Feb 24, 2027) under the same 2017 program.
• Shares owned after the reported transaction are not specified in the provided information.

Context

• This filing reports equity awards (A) and a derivative award tied to performance conditions, not a buy or sell signal. Performance-based restricted awards typically vest only if the company meets specified performance targets and may be withheld for taxes; they do not indicate immediate insider buying or selling.